Ann: Update - Proposed issue of securities - ANP, page-25

Meanwhile back at the ranch...

Sarepta CEO has just purchased $2m of stock on market.

Confidence right there ladies and gentlemen.....and non-binaries!  

Doug now needs to figure out how to spend that US$2B in cash.
_________________

This from Nov 19th.

Those following along with Sarepta Therapeutics, Inc. (NASDAQ:SRPT) will no doubt be intrigued by the recent purchase of shares by Douglas Ingram, President of the company, who spent a stonking US$2.0m on stock at an average price of US$79.94. While that only increased their holding size by 7.4%, it is still a big swing by our standards.
.